Anthera Pharmaceuticals Inc (ANTH1)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
John Craig Thompson
Employees:
21
25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD, CA 94545
(510) 856-5600

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis. It develops phase 3 product candidates, which includes blisibimod and liprotamase. Anthera Pharmaceuticals was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.

Data derived from most recent annual or quarterly report
Market Cap 628.303 Thousand Shares Outstanding26.179 Million Avg 30-day Volume 60.388 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.95
Price to Revenue0.0 Debt to Equity0.0 EBITDA-22.994 Million
Price to Book Value1.5312 Operating Margin0.0 Enterprise Value275.669 Thousand
Current Ratio3.303 EPS Growth0.906 Quick Ratio3.056
1 Yr BETA 0.0707 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth39.19 Altman Z-Score-76.6878 Free Cash Flow to Firm -41.023 Million
View SEC Filings from ANTH1 instead.

View recent insider trading info

Funds Holding ANTH1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ANTH1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MCMANIGLE MARK DREW CHIEF LIQUIDATING OFFICER

0 2018-09-11 0

TRUEX PAUL F

0 2018-01-05 0

SHANAHAN WILLIAM R JR CHIEF MEDICAL OFFICER

0 2018-01-05 0

HENNEY CHRISTOPHER S

0 2018-01-05 0

THOMPSON DAVID E.

0 2018-01-05 0

THOMPSON JOHN CRAIG PRESIDENT & CEO

0 2018-01-05 0

MUELLER BRIAN

0 2018-01-05 0

LIU MAY PRINCIPAL ACCOUNTING OFFICER

0 2018-01-05 0

FURSE BRENT

0 2018-01-05 0

SAGER PHILIP

0 2018-01-05 0

DICKINSON KLARA CHIEF REGULATORY OFFICER

0 2017-05-20 0

OLSON CHARLES V CHIEF TECHNOLOGY OFFICER

0 2017-05-20 0

ENGLE STEVEN B

0 2016-04-27 0

PENNINGTON JAMES INTERIM CHIEF MEDICAL OFFICER

17,688 2016-04-01 0

HISLOP COLIN CHIEF MEDICAL OFFICER

0 2016-02-12 0

ODINK DEBRA CHIEF TECHNOLOGY OFFICER

21,751 2015-10-12 0

ZWEIFACH SANFORD S

0 2015-05-21 0

ZENYAKU KOGYO CO., LTD.

  • 10% Owner
2,795,895 2015-01-27 0

SPIEGELMAN DANIEL K

0 2014-06-13 0

DZIURZYNSKI BOGDAN

10,000 2013-05-31 0

HEALY JAMES

0 2013-05-17 0

LOWE CHRISTOPHER P. CFO AND CHIEF BUSINESS OFFICER

108,915 2013-05-17 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP IV LLC

ISALY SAMUEL D

  • Director
7,462,000 2013-01-30 0

KILFOIL GEORGINA SVP,PRODUCT DEV.& PROJECT MGMT

117,651 2013-01-03 0

THOMPSON PETER A.

  • Director
0 2012-05-08 0

SOFINNOVA VENTURE PARTNERS VI L P

SOFINNOVA MANAGEMENT VI, L.L.C.

SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG

SOFINNOVA VENTURE AFFILIATES VI LP

AZAN ALAIN

POWELL MICHAEL

BUATOIS ERIC

  • 10% Owner
44,969 2011-12-30 0

VANTAGEPOINT VENTURE ASSOCIATES IV LLC

VANTAGEPOINT VENTURE PARTNERS IV Q LP

VANTAGEPOINT VENTURE PARTNERS IV LP

VANTAGEPOINT VENTURE PARTNERS IV PRINCIPALS FUND LP

SALZMAN ALAN E

  • 10% Owner
5,357,528 2011-07-07 0

SANTEL DONALD J

  • Director
0 2011-06-30 0

BIANCHI ANNETTE

  • Director
No longer subject to file 2011-04-19 0

LEHENY A. RACHEL

  • Director
0 2010-09-30 0

TRIAS JOAQUIM SR. VP, PRECLINICAL DEVELOPMEN

  • Officer
198,546 2010-09-21 0

FRITSCH URSULA VP, GLOB. REG. & COMPLIANCE

  • Officer
83,615 2010-06-30 0

LAU STEPHEN VP, CORP. & BUSINESS DEV.

  • Officer
7,000 2010-06-30 0

SOFINNOVA VENTURE PARTNERS VI L P

SOFINNOVA MANAGEMENT VI, L.L.C.

SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG

SOFINNOVA VENTURE AFFILIATES VI LP

BUATOIS ERIC

AZAN ALAIN

POWELL MICHAEL

HEALY JAMES

  • Director
  • 10% Owner
45,809 2010-03-04 0

SOFINNOVA VENTURE PARTNERS VI L P

  • 10% Owner
3,983,230 2010-03-04 0

SOFINNOVA MANAGEMENT VI, L.L.C.

  • 10% Owner
4,072,203 2010-03-04 0

SOFINNOVA VENTURE PARTNERS VI L P

SOFINNOVA MANAGEMENT VI, L.L.C.

  • 10% Owner
0 2010-02-23 0

PENNINGTON JAMES E CHIEF MEDICAL OFFICER & EX. VP

  • Officer
105,140 2010-02-23 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 22:15:04 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 21:45:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 21:15:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 20:45:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 20:15:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 19:45:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 19:15:04 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 18:45:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 18:15:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 17:45:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 17:15:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 16:45:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 16:15:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 15:45:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 15:15:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 14:45:02 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 14:15:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 13:45:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 13:15:03 UTC -20.3209 20.3909 90000
ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 12:45:03 UTC -20.3209 20.3909 90000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments